PTJ
NTLA icon

Paul Tudor Jones’s Intellia Therapeutics NTLA Stock Holding History

Paul Tudor Jones’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
116,908
+27,685
+31% +$387K ﹤0.01% 1949
2026
Q1 		$1.14M Sell
89,223
-99,853
-53% -$1.27M ﹤0.01% 2268
2025
Q4 		$1.7M Buy
+189,076
New +$2.6M ﹤0.01% 1923
2025
Q3 		– Sell
-114,964
Closed -$1.08M – 3707
2025
Q2 		$1.08M Buy
114,964
+46,687
+68% +$383K ﹤0.01% 2080
2025
Q1 		$485K Buy
+68,277
New +$690K ﹤0.01% 2302
2024
Q4 		– Sell
-24,803
Closed -$387K – 3363
2024
Q3 		$510K Sell
24,803
-36,980
-60% -$853K ﹤0.01% 2024
2024
Q2 		$1.38M Buy
61,783
+14,308
+30% +$341K 0.01% 1285
2024
Q1 		$1.31M Buy
+47,475
New +$1.32M 0.01% 1214
2023
Q4 		– Sell
-7,638
Closed -$242K – 2723
2023
Q3 		$242K Buy
+7,638
New +$296K ﹤0.01% 2017
2023
Q1 		– Sell
-44,902
Closed -$1.57M – 2789
2022
Q4 		$1.57M Buy
44,902
+13,817
+44% +$657K 0.03% 787
2022
Q3 		$1.74M Buy
+31,085
New +$1.93M 0.04% 599
2022
Q2 		– Sell
-19,273
Closed -$1.4M – 2390
2022
Q1 		$1.4M Buy
+19,273
New +$1.63M 0.03% 731
2021
Q4 		– Sell
-12,109
Closed -$1.62M – 2825
2021
Q3 		$1.62M Buy
12,109
+4,654
+62% +$705K 0.03% 839
2021
Q2 		$1.21M Buy
+7,455
New +$581K 0.02% 777

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Paul Tudor Jones's NTLA Position: Q2 2026 in Review

Paul Tudor Jones increased its Intellia Therapeutics (NTLA) stake by 31% in Q2 2026, buying an estimated $387K and bringing the position to 116,908 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1949.

Paul Tudor Jones first reported a position in NTLA in Q2 2021 and has held it in 14 quarters since. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Paul Tudor Jones held 116,908 shares of Intellia Therapeutics worth $1.98M as of Q2 2026.
  • Paul Tudor Jones bought 27,685 Intellia Therapeutics shares in Q2 2026, an estimated $387K.
  • Intellia Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1949 holding.
  • Paul Tudor Jones first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • 326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.